Saprima

Saprima is a branded generic combination antibiotic containing sulfamethoxazole and trimethoprim, developed and marketed by S.A. Infinity Europe (S-INFINITY). It belongs to the sulfonamide and pyrimidine inhibitor classes, respectively. The mechanism of action involves a sequential blockade of bacterial folic acid synthesis: sulfamethoxazole inhibits dihydropteroate synthase (the enzyme responsible for incorporating PABA into dihydropteroic acid), and trimethoprim inhibits dihydrofolate reductase (the enzyme that reduces dihydrofolic acid to tetrahydrofolic acid). This dual action results in a synergistic bactericidal effect against a variety of pathogens. Saprima is used to treat bacterial infections such as urinary tract infections, respiratory tract infections, and certain types of pneumonia.

Brand names

Saprima

Other names

Co-trimoxazoleSulfamethoxazole-TrimethoprimSulfamethoxazole + Trimethoprim